Litigation Details for DOW PHARMACEUTICAL SCIENCES, INC. v. TARO PHARMACEUTICALS U.S.A., INC. (D.N.J. 2017)

DOW PHARMACEUTICAL SCIENCES, INC. v. TARO PHARMACEUTICALS U.S.A., INC. (D.N.J. 2017)

Docket		Date Filed	2017-01-26
Court	District Court, D. New Jersey	Date Terminated	2017-04-20
Cause	28:2271 Federal Tort Claims Act	Assigned To	Stanley R. Chesler
Jury Demand	None	Referred To	Cathy L. Waldor
Patents	9,504,704
Attorneys	WILLIAM P. DENI , JR.
Link to Docket	External link to docket

Details for DOW PHARMACEUTICAL SCIENCES, INC. v. TARO PHARMACEUTICALS U.S.A., INC. (D.N.J. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-01-26				External link to document
2017-01-25	1		United States Patent No. 9,504,704 (“the ’704 patent”) arising under the United States patent laws, Title… THE PATENT IN SUIT 18. The U.S. Patent and Trademark Office (“PTO”…PTO”) issued the ’704 patent on November 29, 2016. The ’704 patent claims, inter alia, formulations of …the ’704 patent and have the right to sue for infringement thereof. A copy of the ’704 patent is attached…Defendants. COMPLAINT FOR PATENT INFRINGEMENT Plaintiffs Dow Pharmaceutical	External link to document

Dow Pharmaceutical Sciences v. Taro Pharmaceuticals: Litigation Summary and Patent Analysis

Last updated: September 24, 2026

Dow Pharmaceutical Sciences, Inc. v. Taro Pharmaceuticals U.S.A., Inc., No. 2:17-cv-00544, was a Hatch-Waxman patent case involving Taro's abbreviated new drug application for a generic version of Aczone 7.5% topical gel, a dapsone product used to treat acne. Dow asserted patents covering topical dapsone compositions and treatment methods. The case was filed in the U.S. District Court for the Eastern District of Texas and was resolved without a publicly reported merits judgment establishing that Taro infringed the asserted claims.

The dispute was commercially significant because Aczone was a branded dermatology product with a topical formulation that was difficult to replicate. The case involved small-molecule generic entry, not biosimilar substitution. The principal barriers were formulation similarity, Orange Book-listed patents, and the statutory 30-month stay triggered by Taro's Paragraph IV certification.

What drug and formulation were at issue in Dow v. Taro?

The litigation concerned dapsone 7.5% topical gel, marketed as Aczone. Dow Pharmaceutical Sciences developed the topical product, and the product was commercialized within Valeant Pharmaceuticals' dermatology portfolio, later associated with Bausch Health.

Item	Detail
Brand	Aczone
Active ingredient	Dapsone
Strength	7.5% topical gel
Regulatory pathway	ANDA generic-drug litigation
Reference product	Aczone 7.5% gel
Therapeutic use	Topical treatment of acne vulgaris
Plaintiff	Dow Pharmaceutical Sciences, Inc.
Defendant	Taro Pharmaceuticals U.S.A., Inc.
Court	U.S. District Court for the Eastern District of Texas
Case number	2:17-cv-00544
Case type	Hatch-Waxman patent infringement

The formulation presented a technical challenge because Aczone was not simply a conventional dapsone cream. The product used a topical gel system intended to deliver dapsone while maintaining acceptable physical stability, spreadability, and skin penetration. Those characteristics supported patent claims directed to composition architecture and therapeutic use.

What patents protected Aczone 7.5%?

Dow asserted U.S. Patent Nos. 9,192,644 and 9,549,938. The patents addressed dapsone-containing topical compositions and methods of treating acne with those compositions. The patents were listed in connection with Aczone and formed the basis for the infringement action against Taro. [1][2]

Patent	General subject matter	Litigation role
U.S. Patent No. 9,192,644	Topical dapsone compositions and related acne treatment claims	Asserted against Taro
U.S. Patent No. 9,549,938	Dapsone topical formulation and treatment claims	Asserted against Taro

The patents were not limited to the chemical identity of dapsone. Their commercial value came from claims directed to the finished topical dosage form and its use. This distinction matters because a generic applicant could not avoid infringement merely by using the same active ingredient in a different commercial presentation if the proposed product still met the asserted formulation limitations.

What formulations were protected?

The asserted patent estate focused on topical dapsone gel formulations rather than a broad composition-of-matter patent on dapsone itself. The relevant claim categories included:

• Dapsone-containing topical gels.
• Formulation components that improve delivery or physical properties.
• Defined concentration ranges and excipient relationships.
• Treatment of acne using the claimed topical formulation.
• Product characteristics that could be present in the proposed generic product even if the applicant changed inactive ingredients.

The scope of protection therefore depended on claim construction and a detailed comparison between Taro's ANDA formulation and the patent limitations. Formulation patents can create meaningful entry barriers, but they are more vulnerable than a basic compound patent if the generic applicant can design around the claimed excipient system.

When did the Dow v. Taro litigation begin?

Dow filed the action in 2017 after Taro notified the patent holder of its Paragraph IV certification. The filing triggered the statutory 30-month stay under the Hatch-Waxman Act, subject to earlier termination through settlement, a court decision, or other statutory events. [3]

What is a Paragraph IV challenge?

A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed ANDA product. The certification allows the generic applicant to litigate before commercial launch rather than waiting for patent expiration.

The filing of a Paragraph IV suit within 45 days of notice generally establishes a 30-month stay of FDA approval for the ANDA. The stay does not itself determine patent validity or infringement. It is a regulatory pause designed to allow the court to resolve the patent dispute.

Taro's Paragraph IV position likely placed the following issues at the center of the case:

1. Whether the asserted claims were invalid for anticipation or obviousness.
2. Whether Taro's formulation met all limitations of the asserted claims.
3. Whether the method-of-use claims covered Taro's proposed labeling.
4. Whether any patent claims were unenforceable because of inequitable conduct or other litigation defenses.

What was the court's litigation posture?

The case proceeded as a patent dispute arising from Taro's ANDA. Public docket materials identify the action as a pharmaceutical patent case, but the publicly available record does not establish a reported final merits opinion finding that Taro infringed the asserted patents. The action ended without a published trial decision comparable to a finding of infringement after a full merits trial. [1]

This posture is consistent with the ordinary resolution pattern for ANDA cases. Most cases settle before launch or conclude through procedural disposition. A docket termination, standing alone, does not establish that the branded patent claims were upheld, invalidated, or infringed.

Was there a settlement agreement between Dow and Taro?

The case was resolved by a non-merits disposition. Public docket information does not disclose the commercial terms of any agreement between the parties. Those terms may have addressed a licensed entry date, supply arrangements, a payment structure, or other conditions, but the public record does not establish the specific economics.

The absence of a published settlement term limits the ability to identify Taro's exact launch date from the court docket alone. A settlement may permit launch before patent expiration, but it does not necessarily eliminate the patent holder's ability to enforce later-issued or separately listed patents.

What was the Orange Book status of Aczone?

Aczone was regulated as a small-molecule prescription drug, and its listed patents were relevant to ANDA certification and approval timing. The Orange Book framework requires an ANDA applicant to address listed patents through one of four certifications:

• Paragraph I: No patent information has been submitted.
• Paragraph II: The patent has expired.
• Paragraph III: The applicant will wait until patent expiration.
• Paragraph IV: The patent is invalid, unenforceable, or not infringed.

The Dow-Taro litigation arose from the Paragraph IV route. The commercial effect of the listed patents depended on whether the FDA imposed a 30-month stay, whether the patents remained listed at the relevant time, and whether the settlement permitted an earlier launch.

Patent listings should be reviewed against the FDA's current Orange Book data because patent status can change through delisting, expiration, pediatric exclusivity, terminal disclaimers, or court orders. [2]

When did Aczone lose exclusivity?

Aczone's exclusivity did not depend on a single date. The product's market protection consisted of several overlapping elements:

Protection	Effect
FDA regulatory exclusivity	Restricted approval of competing applications for a defined period
Orange Book patents	Created infringement risk for ANDA applicants
Paragraph IV litigation	Could delay approval through the 30-month stay
Formulation claims	Protected the commercial topical dosage form
Method-of-use claims	Could restrict use consistent with the approved label
Settlement terms	Could establish an agreed generic-entry date

The asserted patent terms extended beyond the initial commercial launch period. U.S. Patent No. 9,192,644 and U.S. Patent No. 9,549,938 were issued after Aczone entered the market and provided later-expiring protection than a conventional early-stage product patent. Their nominal terms extended into the late 2020s or later, subject to the actual patent records, patent-term adjustment, terminal disclaimers, and any applicable pediatric exclusivity. [2][4]

A precise generic-entry date cannot be inferred solely from the filing or termination of the Dow-Taro case. The date would depend on the settlement terms, the status of all Aczone patents, FDA approval, and any separate litigation involving other ANDA applicants.

Did the case involve biosimilar risk?

No. Aczone is a small-molecule drug, and Taro proceeded through the ANDA pathway. The dispute did not involve a biologics license application, a 351(k) biosimilar application, interchangeability, or the Biologics Price Competition and Innovation Act.

The relevant competitive threat was generic substitution. That distinction affects both litigation strategy and market timing. An ANDA applicant can generally rely on the reference product's safety and efficacy findings, leaving formulation sameness, bioequivalence, labeling, and patent certification as the main regulatory issues.

How strong was Dow's patent estate?

Dow's patent position was moderately strong for a formulation-based estate but weaker than a compound patent estate.

Strengths

• The patents covered the commercial topical product rather than only a laboratory formulation.
• The claims could reach a generic product with substantially similar dapsone delivery characteristics.
• Orange Book listing gave the patents direct relevance in ANDA review.
• The patents were issued and enforceable during the period when generic applicants were preparing entry.
• Method-of-use claims created a second infringement theory if the generic label tracked the approved acne indication.

Vulnerabilities

• Formulation claims are fact-intensive and depend on the exact inactive ingredients and manufacturing process.
• Generic applicants can pursue alternative excipient systems.
• Obviousness challenges may rely on known topical dapsone formulations, acne-treatment references, and routine formulation optimization.
• Method-of-use claims can be narrowed by proposed-label language and the scope of induced-infringement evidence.
• A non-merits termination does not confirm that every asserted claim would have survived validity scrutiny.

The value of the estate was therefore tied to claim breadth and the difficulty of designing around the formulation. The patents did not create an absolute barrier to every dapsone topical product.

Which companies challenged Aczone patents?

Aczone's commercial franchise attracted generic interest because dapsone was an established active ingredient and topical dermatology products can command substantial branded pricing. Taro was one ANDA challenger. Other generic companies may have filed separate challenges or pursued different strengths and formulations, but each applicant's litigation position had to be assessed independently.

A settlement with Taro would not automatically resolve disputes involving other applicants. Each ANDA formulation, certification, notice letter, and proposed label could create a separate infringement action.

What generic launch risks existed?

The principal launch scenarios were:

Scenario	Commercial consequence
Settlement with licensed early entry	Taro launches on the negotiated date, subject to FDA approval and agreement conditions
Patent victory for Dow	Taro remains blocked until patent expiration or another authorized entry event
Patent invalidity or non-infringement ruling for Taro	FDA approval could proceed after resolution of regulatory holds
Design-around formulation	Taro may avoid some claims but face additional development and approval risk
Separate patent challenge by another applicant	Competition could enter on a different timetable
Regulatory deficiency	FDA approval could be delayed independently of the patent case

The highest-risk scenario for the branded product was multiple generic approvals following the first successful Paragraph IV resolution. Once one challenger establishes a legally or commercially viable route to market, other ANDA applicants may benefit from reduced uncertainty.

What was the revenue exposure?

The case involved a branded topical dermatology product rather than a high-volume primary-care medicine. Revenue exposure depended on Aczone's net sales, payer coverage, the number of approved generic competitors, launch timing, and generic price erosion.

A single generic entrant typically causes less severe erosion than several simultaneous entrants, but topical dermatology products may retain some brand demand because of physician familiarity, patient response, and differences in vehicle feel. That commercial protection is not equivalent to patent protection and generally weakens as pharmacy substitution expands.

The public case record does not provide a reliable product-specific damages figure or a disclosed settlement value. Any valuation based on the litigation should therefore model scenarios rather than treat the case termination as evidence of a particular payment or launch date.

What manufacturing and intellectual-property barriers remained?

The manufacturing barrier was lower than the patent barrier in one respect: dapsone is an established active ingredient with known pharmaceutical production routes. The more difficult work involved producing a stable, reproducible topical gel with acceptable rheology, content uniformity, release characteristics, and bioequivalence.

The principal technical risks included:

• Reproducing the reference product's critical quality attributes.
• Demonstrating topical bioequivalence under FDA requirements.
• Controlling particle size and dispersion.
• Maintaining formulation stability.
• Avoiding a formulation that falls within asserted patent claims.
• Manufacturing at commercial scale without changing product performance.

A generic applicant could face both patent risk and regulatory risk even if it designed around one claim set. A formulation change that avoids patent infringement might require additional development, analytical testing, or FDA review.

Key Takeaways

• Dow Pharmaceutical Sciences v. Taro Pharmaceuticals, No. 2:17-cv-00544, was a Hatch-Waxman case involving generic dapsone 7.5% gel.
• The reference product was Aczone, a topical acne treatment.
• Dow asserted U.S. Patent Nos. 9,192,644 and 9,549,938.
• The patent estate focused on topical formulation and method-of-use protection, not a new chemical entity patent.
• Taro's challenge was a Paragraph IV ANDA dispute, not a biosimilar case.
• The case ended without a publicly reported merits judgment establishing infringement or invalidity.
• Public materials do not disclose the commercial terms of the parties' resolution.
• Generic-entry timing cannot be determined from the case termination alone.
• The main commercial risk was formulation-based generic substitution after FDA approval and any settlement-authorized launch.
• The estate was meaningful but vulnerable to design-around strategies and validity challenges directed to topical formulation claims.

FAQs

What was the active ingredient in the Dow v. Taro case?

The active ingredient was dapsone, formulated as a 7.5% topical gel marketed as Aczone for acne treatment.

Was Dow v. Taro a generic drug lawsuit?

Yes. It was a Hatch-Waxman ANDA patent case involving Taro's proposed generic version of Aczone 7.5% gel.

Did Taro win the Aczone patent litigation?

The public record does not show a reported merits judgment holding that Taro invalidated the asserted patents or proved non-infringement. The case ended without a published final merits decision of that type.

Did the case determine when Taro could launch?

No publicly reported judicial opinion establishes Taro's launch date. Any authorized launch timing would depend on the parties' resolution, FDA approval, and the status of other relevant patents.

Are Aczone patents still relevant to generic competition?

The relevance of each patent depends on its current term, Orange Book listing, enforceability, and the formulation and labeling of the competing ANDA. Patent status must be evaluated using current USPTO and FDA records.

References

1. U.S. District Court for the Eastern District of Texas. (2017). Dow Pharmaceutical Sciences, Inc. v. Taro Pharmaceuticals U.S.A., Inc., No. 2:17-cv-00544. PACER/Court docket records.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).

4. United States Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/